Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Surgery. 2011 Feb 5;149(4):484–495. doi: 10.1016/j.surg.2010.11.014

FIG. 2.

FIG. 2

Multiple treatment cycles of A or/and L-A-5-RIP-TK/GCV treatment suppresses growth of human pancreas cancer xenografts. Two weeks after i.p. injection of PANC-1 cells, SCID mice were divided into five groups (30 animals/group) and treated as follows: (1) 4 cycles of GCV, (2) 1 cycle of A-5-RIP-TK/GCV, (3) 1 cycle of A-5-RIP-TK/GCV+1 cycles of L-A-5-RIP-TK/GCV, (4) 1 cycle of A-5-RIP-TK/GCV+2 cycles of L-A-5-RIP-TK/GCV, (5) 1 cycle of A-5-RIP-TK/GCV+3 cycles of L-A-RIP-TK/GCV. At 4 months after treatment, at least five mice were sacrificed. Percentages of tumor-free animals in different groups were compared using χ2-test significance (A)Tumor size was measured and compared using Student's t-test (B) with P< 0.05 representing significance. Tumor growth was significantly suppressed in all treated mice compared with controls.